Clarifying the Antipruritic Effects of a Bile Acid Inhibitor
A recent correspondence in The Lancet Gastroenterology & Hepatology addresses questions about the GLISTEN trial, which investigated the ileal bile acid transporter inhibitor linerixibat for treating pruritus. The authors respond to points raised by other experts, offering clarifications on the trial’s methodology and findings. This exchange highlights the ongoing scientific discourse around targeting bile acid transport as a therapeutic strategy for cholestatic pruritus, a burdensome symptom in liver diseases like primary biliary cholangitis.
Why it might matter to you: For gastroenterologists and hepatologists, this dialogue underscores the clinical relevance of bile acid metabolism in managing cholestatic pruritus. It points to the need for a nuanced understanding of new drug mechanisms, like ileal bile acid transporter inhibition, to effectively assess their place in therapy. This development is directly pertinent to patient care strategies for chronic liver conditions where pruritus significantly impacts quality of life.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
